Vivek Jayaraman is recorded as Board Member and CEO at Cerus Corp (CERS) since July 1, 2026 and COO at Cerus Corp (CERS). The newest filing on record that lists Vivek Jayaraman as COO at Cerus Corp (CERS) is dated April 22, 2026. Cerus Corp reported in an 8-K filed March 16, 2026 that Vivek Jayaraman was appointed member of the Company's Board of Directors, effective July 1, 2026. Cerus Corp reported in an 8-K filed March 16, 2026 that Vivek Jayaraman was appointed President and Chief Executive Officer, effective July 1, 2026. The proxy statement of Cerus Corp reports total compensation of $2,204,198 for Vivek Jayaraman in fiscal 2025, including a base salary of $565,768. Disclosed compensation is on record for 9 fiscal years. Vivek Jayaraman has spoken on 22 earnings calls across 1 company, most recently for Cerus Corp on July 30, 2026. Cerus Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Cerus Corp includes William M. Greenman (CEO, Chairman and Board Member), William "Obi" Greenman (Chairman), William “Obi” Greenman (Chairman) and 7 others.
“Mr. Jayaraman will also be appointed to the Board, effective on the Effective Date.”
“On March 16, 2026, Cerus Corporation (the "Company") announced that Vivek Jayaraman, the Company's Chief Operating Officer, will be appointed as the Company's President and Chief Executive Officer, effective July 1, 2026 (the "Effective Date").”
“At Cirrus, our mission is clear, to expand access to safe blood for patients around the world. As we enter 2026, we are focused on delivering against that mission while executing on three core priorities, driving sustainable double-digit growth, advancing innovation, and strengthening our financial foundation.”
“We finished 2025 on a high note with another quarter of strong performance across our global platelet franchise, continued positive traction with the international launch of our INT200 illuminator and increasing momentum in our U.S. IFC business.”
“As Obi mentioned, we delivered another strong quarter of commercial execution in Q2. Our record product revenue underscores the progress we are making across multiple geographies and throughout our INTERCEPT product portfolio.”
“As Obi stated, we delivered another solid quarter of operating performance in Q1 ‘25. Our double-digit year-over-year growth was the result of strength across our global franchise.”
